In this episode of the Think Small Podcast, Jack Oswald, co-founder, CEO, and CTO of Isothrive, shares one of the most counter intuitive founder stories the show has featured: a company that deliberately walked away from a working consumer product with happy customers, real revenue, and zero FDA headaches, because the science demanded something harder. Isothrive started in 2013 around a single hypothesis that the modern diet has stripped out a specific prebiotic molecule that gut bacteria depend on, built a supplement that generated revenue and data, and then used that foundation to pivot into clinical-stage drug development when an inordinately high percentage of customers began self-reporting the spontaneous resolution of chronic heartburn, a condition that had plagued many of them for decades. Thirty-plus patents, a just-completed phase two tr ...